ORGAN ON A CHIP MARKET ANALYSIS

Organ On A Chip Market Size and Trends

The Global Organ-on-a-Chip Market is estimated to be valued at USD 155.3 Mn in 2025 and is expected to reach USD 1,211.1 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 34.1% from 2025 to 2032.

Key Takeaways of the Organ-on-a-Chip Market:

• In terms of products & service, the products segment is expected to contribute the highest share of the market with 52.1% in 2025.
• In terms of application, the toxicology testing segment is expected to contribute the highest share of the market with 33.4% in 2025.
• In terms of end user, the pharmaceutical and biotechnology companies segment is expected to contribute the highest share of the market with 43.4% in 2025.
• North America is expected to top the market with 37.4% share, followed by Asia pacific with 27.4% share in 2025.

Market Overview:

The increasing need for alternative methods for drug screening and the growing focus on developing organ-level models of disease pathology are major factors expected to drive the demand for organ-on-a-chip devices. Furthermore, increasing collaborations between research academics and market players to develop more sophisticated organ-on-a-chip platforms will further augment the market growth. Availability of funding from private and public organizations for research on microfluidic devices is also expected to propel the organ-on-a-chip market during 2025-2032. However, the high costs associated with organ-on-a-chip systems may hamper market growth to some extent during the forecast years.

To learn more about this report, Request sample copy

Key Developments:

• In October 2024, InSphero, a leader in 3D cell culture technology, launched a next-generation liver-on-a-chip platform to enhance the assessment of drug-induced liver injury, delivering more reliable data for preclinical studies
• In October 2024, Allevi Inc., renowned for its 3D bioprinting solutions, introduced a new bioprinting kit for creating customizable organ-on-a-chip models, simplifying the fabrication of tissue-specific chips for researchers
• In September 2024, Hesperos, a pioneer in human-on-a-chip systems, secured a significant grant to develop a multi-organ-on-a-chip system for modeling complex human diseases, advancing personalized medicine applications
• In September 2024, Emulate Inc., a key player in organ-on-a-chip technology, announced a collaboration with a leading pharmaceutical company to leverage its platform for advanced drug testing, aiming to improve predictive accuracy in human biology models
• In August 2024, MIMETAS BV, a global leader in organ-on-a-chip platforms, expanded its OrganoPlate technology to include a kidney-on-a-chip model, enabling more accurate studies of renal diseases and drug nephrotoxicity

Top Strategies Followed by Global Organ-on-a-Chip Market Players

• Established Players: Leading organ-on-a-chip companies extensively focus on research and development to introduce innovative solutions.
  • For instance, in December 2022, Quris, an AI-driven innovator in the pharmaceutical industry, announced an additional US$ 9 million in seed funding, bringing the total to US$ 37 million. The funding will accelerate Quris’ Bio-AI clinical prediction platform, which uses a patented patient-on-chip system and AI to simulate human reactions to drugs, reducing reliance on animal testing and cutting drug development costs.
• Mid-Level Players: Mid-level companies focus on delivering quality, budget-friendly products targeting price-sensitive consumers. For example, Altis Biosystems offers a stem cell platform to recreate the human intestinal epithelium, providing cost-effective solutions for drug discovery and toxicity testing.
  • For example, Altis Biosystems offers a stem cell platform to recreate the human intestinal epithelium, providing cost-effective solutions for drug discovery and toxicity testing.
• Small-Scale Players: Small players often target niche markets with unique features or innovative products. For instance, Bi/ond develops customizable organ-on-a-chip solutions for in vitro assays, focusing on specific organ models to cater to specialized research needs. Adopting cutting-edge technologies is essential for competitiveness. Bi/ond utilizes advanced microfabrication techniques to develop its organ-on-a-chip platforms, ensuring high precision and functionality.

Emerging Startups - Organ-on-a-Chip Industry Ecosystem

• Innovative Technologies: Recent startups are actively working on advanced technological solutions. For example, Cherry Biolabs develops 'body-on-a-chip' platforms using smart microsensors and tissue engineering. Similarly, AxoSim focuses on developing neural organoids integrated with AI algorithms. If successful, these innovative attempts could transform drug testing process and reduce reliance on animal models. For instance, AI-enhanced chips may predict complex human reactions with more accuracy. This will highly influence the industry by enabling personalized testing and cutting costs.
• Sustainable Solutions: Some startups are promoting sustainability in the sector. For example, Elveflow creates tissue chips using 3D bioprinting of natural materials like alginate and collagen extracted from seaweed and animal tissues respectively. This helps mimic natural organ microenvironments accurately while reducing environmental footprint. Another promising startup grows self-assembled liver and bone tissues entirely from donor cells without scaffolds. This novel approach could enable generating patient-specific implants through methods that cause zero biowaste.